Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain

News provided by

29 May, 2023, 11:00 ET

Share this article

The prevalence of diabetic retinopathy has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of diabetic retinopathy and the growing research and development activities to develop novel therapies to treat diabetic retinopathy to drive the market. The companies developing the potential therapies in the last stage of development include Roche, Kodiak Sciences, Novartis, and several others.

LAS VEGAS, May 29, 2023 /PRNewswire/ -- DelveInsight's 'Diabetic Retinopathy Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline diabetic retinopathy therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the diabetic retinopathy pipeline domain.

Key Takeaways from the Diabetic Retinopathy Pipeline Report

Request a sample and discover the recent advances in diabetic retinopathy drug treatment @ Diabetic Retinopathy Pipeline Report

The diabetic retinopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage diabetic retinopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the diabetic retinopathy clinical trial landscape.

Diabetic Retinopathy Overview

Diabetic retinopathy is a microvascular condition caused by diabetes mellitus's long-term effects. Diabetic retinopathy can cause vision-threatening retinal damage, eventually leading to blindness. It is found in one-third of patients with diabetes and is linked to an increased risk of life-threatening systemic vascular consequences such as stroke, coronary heart disease, and heart failure. Diabetic retinopathy affects an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) of people with type 1 diabetes in the United States.

The keys to avoiding diabetic retinopathy blindness are early detection and appropriate intervention. Several large studies have found that the onset of diabetic retinopathy does not usually occur within the first 5 years of type 1 diabetes diagnosis. In contrast, the onset of type 2 diabetes is frequently more subtle, and as a result, retinal damage may be evident at the time of diagnosis. As a result, screening for diabetic retinopathy is advised in type 2 diabetics at the time of diagnosis.

Find out more about drugs for diabetic retinopathy @ New Diabetic Retinopathy Drugs

A snapshot of the Diabetic Retinopathy Pipeline Drugs mentioned in the report:

Drugs

Company

Phase

MoA

RoA

KSI-301

Kodiak Sciences

Phase III

Vascular endothelial growth factors inhibitor

Intravitreal

Brolucizumab

Novartis

Phase III

Vascular endothelial growth factor A inhibitor

Intravitreal

RGX 314

Regenxbio Inc.

Phase II

Gene transference

Runcaciguat modified release

Bayer

Phase II

Guanylate cyclase stimulants

Oral

OTT-166

OcuTerra Therapeutics

Phase II

Integrin alphaVbeta3 antagonists; Integrin alphaVbeta6 inhibitors; Integrin alphavbeta8 inhibitors

Topical

APX3330

Ocuphire Pharma

Phase II

Angiogenesis inhibitors; APEX1 protein inhibitors; DNA apurinic apyrimidinic site lyase inhibitors

Oral

OTX-TKI

Ocular Therapeutix

Phase I

Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists

Intravitreal

Learn more about the emerging diabetic retinopathy pipeline therapies @ Diabetic Retinopathy Clinical Trials

Diabetic Retinopathy Therapeutics Assessment

The diabetic retinopathy pipeline report proffers an integral view of diabetic retinopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Diabetic Retinopathy Pipeline Report

Dive deep into rich insights for new drugs for diabetic retinopathy treatment; visit @ Diabetic Retinopathy Medications

Table of Contents

Diabetic Retinopathy Pipeline Report Introduction

Diabetic Retinopathy Pipeline Report Executive Summary

Diabetic Retinopathy Pipeline: Overview

Diabetic Retinopathy Clinical Trial Therapeutics

Diabetic Retinopathy Pipeline: Late-Stage Products (Pre-registration)

Diabetic Retinopathy Pipeline: Late-Stage Products (Phase III)

Diabetic Retinopathy Pipeline: Mid-Stage Products (Phase II)

Diabetic Retinopathy Pipeline: Early-Stage Products (Phase I)

Diabetic Retinopathy Pipeline Therapeutics Assessment

10.

Inactive Products in the Diabetic Retinopathy Pipeline

11.

Company-University Collaborations (Licensing/Partnering) Analysis

12.

Key Companies

13.

Key Products in the Diabetic Retinopathy Pipeline

14.

Unmet Needs

15.

Market Drivers and Barriers

16.

Future Perspectives and Conclusion

17.

Analyst Views

18.

Appendix

For further information on the diabetic retinopathy pipeline therapeutics, reach out @ Diabetic Retinopathy Drug Treatment

Related Reports

Diabetic Retinopathy Market

Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic retinopathy companies, including Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, among others.

Diabetic Retinopathy Epidemiology Forecast

Diabetic Retinopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and diabetic retinopathy epidemiology trends.

Proliferative Diabetic Retinopathy Pipeline

Proliferative Diabetic Retinopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key proliferative diabetic retinopathy companies, including Kubota Vision, among others.

Diabetic Neuropathy Pipeline

Diabetic Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, among others.

Diabetic Neuropathy Market

Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, among others.

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

DelveInsight Business Research, LLP